(Total Views: 61)
Posted On: 11/10/2025 3:56:25 PM
Post# of 225
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida
NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using the Ampa “one day” (ONE-D) protocol for treatment-resistant depression—the first deployment of its kind in Florida and among the first nationwide. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, which in peer-reviewed studies have shown response rates of 87% and remission rates of 72% in nonrandomized trials. Under the direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering the protocol, with six Florida locations expected by year-end. Dr. Cohen said the results “have the potential to change the paradigm of TMS therapy” from months-long regimens to a rapid, one-day approach that may transform care for millions battling depression and PTSD.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using the Ampa “one day” (ONE-D) protocol for treatment-resistant depression—the first deployment of its kind in Florida and among the first nationwide. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, which in peer-reviewed studies have shown response rates of 87% and remission rates of 72% in nonrandomized trials. Under the direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering the protocol, with six Florida locations expected by year-end. Dr. Cohen said the results “have the potential to change the paradigm of TMS therapy” from months-long regimens to a rapid, one-day approach that may transform care for millions battling depression and PTSD.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
